Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSF NASDAQ:ENDP NASDAQ:INVA NASDAQ:ITCI NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsINVAInnoviva$17.40+1.1%$19.12$16.52▼$22.00$1.08B0.4687,200 shs660,639 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ATBPHTheravance Biopharma$14.01-2.1%$13.95$7.90▼$15.15$720.67M-0.03303,639 shs178,751 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ENDPEndo International0.00%0.00%0.00%0.00%0.00%INVAInnoviva+1.10%+4.38%-9.33%-9.75%-12.34%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+71.46%TBPHTheravance Biopharma-2.10%+1.16%+0.94%+23.98%+61.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsINVAInnoviva$17.40+1.1%$19.12$16.52▼$22.00$1.08B0.4687,200 shs660,639 shsITCIIntra-Cellular Therapies$131.87$131.87$70.90▼$131.98$14.05B0.691.57 million shsN/ATBPHTheravance Biopharma$14.01-2.1%$13.95$7.90▼$15.15$720.67M-0.03303,639 shs178,751 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%ENDPEndo International0.00%0.00%0.00%0.00%0.00%INVAInnoviva+1.10%+4.38%-9.33%-9.75%-12.34%ITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+71.46%TBPHTheravance Biopharma-2.10%+1.16%+0.94%+23.98%+61.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/AENDPEndo International 0.00N/AN/AN/AINVAInnoviva 2.71Moderate Buy$37.60116.09% UpsideITCIIntra-Cellular Therapies 2.11Hold$121.29-8.03% DownsideTBPHTheravance Biopharma 3.00Buy$23.0064.17% UpsideCurrent Analyst Ratings BreakdownLatest ENDP, ITCI, INVA, TBPH, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025INVAInnovivaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/27/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025TBPHTheravance BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00ENDPEndo International$2.99B0.00N/A0.06($13.60) per share0.00INVAInnoviva$358.71M3.06$3.47 per share5.02$11.03 per share1.58ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44TBPHTheravance Biopharma$77.21M9.14N/AN/A$3.57 per share3.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AENDPEndo International-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/AINVAInnoviva$23.39M$0.3156.1311.23N/A10.44%18.67%9.92%11/5/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ATBPHTheravance Biopharma-$56.42M$0.2458.3840.03N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest ENDP, ITCI, INVA, TBPH, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025TBPHTheravance Biopharma-$0.03N/AN/AN/A$19.89 millionN/A11/5/2025Q3 2025INVAInnoviva$0.46N/AN/AN/A$91.31 millionN/A8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AENDPEndo InternationalN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87ENDPEndo InternationalN/A1.861.62INVAInnoviva0.362.642.44ITCIIntra-Cellular TherapiesN/A7.667.51TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AENDPEndo International80.39%INVAInnoviva99.12%ITCIIntra-Cellular Therapies92.33%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%ENDPEndo International1.20%INVAInnoviva2.25%ITCIIntra-Cellular Therapies2.60%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableENDPEndo International3,103235.14 million232.32 millionNo DataINVAInnoviva10063.02 million61.60 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableENDP, ITCI, INVA, TBPH, and BLUSF HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Stock Crosses Above Fifty Day Moving Average - Here's WhyOctober 17, 2025 | marketbeat.comTheravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System AtrophyOctober 16, 2025 | businesswire.comTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual MeetingOctober 14, 2025 | prnewswire.comAnalysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $23.00October 12, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Earns "Hold (C)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Buy" from AnalystsOctober 7, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Sets New 12-Month High - Time to Buy?October 6, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month High - Here's What HappenedSeptember 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Takes $264,000 Position in Theravance Biopharma, Inc. $TBPHSeptember 29, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12, 2025 | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12, 2025 | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11, 2025 | zacks.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comTheravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...August 25, 2025 | finanznachrichten.deTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...August 25, 2025 | finance.yahoo.comTheravance Biopharma completes enrollment in CYPRESS studyAugust 25, 2025 | msn.comTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System AtrophyAugust 25, 2025 | prnewswire.comTheravance Biopharma Settles Patent Dispute with CiplaAugust 20, 2025 | msn.comTheravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/YAugust 13, 2025 | zacks.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comTheravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENDP, ITCI, INVA, TBPH, and BLUSF Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Endo International NASDAQ:ENDPEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Innoviva NASDAQ:INVA$17.40 +0.19 (+1.10%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$17.23 -0.17 (-1.01%) As of 10/21/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Intra-Cellular Therapies NASDAQ:ITCIIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Theravance Biopharma NASDAQ:TBPH$14.01 -0.30 (-2.10%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$14.01 0.00 (0.00%) As of 10/21/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
